Stifel analyst Annabel Samimy raised the firm’s price target on Oculis (OCS) to $40 from $35 and keeps a Buy rating on the shares as part of a 2026 outlook note for the analyst’s Biopharma coverage.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OCS: